Portola Pharmaceuticals Inc. (NASDAQ:PTLA)’s share price traded up 3.2% during mid-day trading on Tuesday . The company traded as high as $20.08 and last traded at $19.84, with a volume of 797,595 shares trading hands. The stock had previously closed at $19.22.

A number of equities analysts have recently issued reports on the stock. Citigroup Inc. increased their price target on shares of Portola Pharmaceuticals from $29.00 to $36.00 and gave the company a “buy” rating in a report on Friday, May 27th. Credit Suisse Group AG reiterated a “hold” rating and issued a $30.00 price target on shares of Portola Pharmaceuticals in a report on Thursday, August 18th. Zacks Investment Research cut shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Cowen and Company reissued a “buy” rating on shares of Portola Pharmaceuticals in a research note on Thursday, August 18th. Finally, Morgan Stanley lowered their price objective on shares of Portola Pharmaceuticals from $61.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, August 19th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Portola Pharmaceuticals presently has an average rating of “Buy” and an average price target of $32.64.

The stock has a 50 day moving average of $24.41 and a 200-day moving average of $25.49. The stock’s market cap is $1.15 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.18. The firm had revenue of $4.23 million for the quarter, compared to analyst estimates of $4.38 million. During the same period last year, the firm posted ($1.12) EPS. The business’s revenue was up 75.0% compared to the same quarter last year. Equities analysts predict that Portola Pharmaceuticals Inc. will post ($4.39) earnings per share for the current fiscal year.

Other institutional investors have recently made changes to their positions in the company. Jennison Associates LLC increased its position in shares of Portola Pharmaceuticals by 31.1% in the fourth quarter. Jennison Associates LLC now owns 858,523 shares of the biopharmaceutical company’s stock valued at $44,171,000 after buying an additional 203,505 shares during the period. Wells Fargo & Company MN increased its position in shares of Portola Pharmaceuticals by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 293,921 shares of the biopharmaceutical company’s stock valued at $15,121,000 after buying an additional 10,544 shares during the period. Morgan Stanley increased its position in shares of Portola Pharmaceuticals by 7.2% in the fourth quarter. Morgan Stanley now owns 234,948 shares of the biopharmaceutical company’s stock valued at $12,089,000 after buying an additional 15,853 shares during the period. New York State Common Retirement Fund increased its position in shares of Portola Pharmaceuticals by 3.6% in the fourth quarter. New York State Common Retirement Fund now owns 68,123 shares of the biopharmaceutical company’s stock valued at $3,505,000 after buying an additional 2,376 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Portola Pharmaceuticals by 17.2% in the fourth quarter. California Public Employees Retirement System now owns 56,000 shares of the biopharmaceutical company’s stock valued at $2,881,000 after buying an additional 8,200 shares during the period.

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.